Kazia Therapeutics (KZIA) Net Income towards Common Stockholders (2009 - 2011)

Kazia Therapeutics has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$926122.0 in Q4 2011.

• For the quarter ending Q4 2011, Net Income towards Common Stockholders rose 81.99% year-over-year to -$926122.0; the trailing twelve-month figure through Aug 2013 stood at -$926122.0 (changed N/A YoY), and the FY2025 full-year result was -$13.3 million, up 24.87% from the prior year.
• Net Income towards Common Stockholders for Q4 2011 stood at -$926122.0, up from -$5.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$926122.0 in Q4 2011, with the low at -$5.8 million in Q4 2009.
• Historically, Net Income towards Common Stockholders has averaged -$3.9 million across 3 years, with a median of -$4.5 million in 2009.
• Annual changes were most pronounced in 2010 — Net Income towards Common Stockholders gained 11.52% — and 2011, when it surged 81.99%.
• Kazia Therapeutics' Net Income towards Common Stockholders stood at -$5.8 million in 2009, then advanced by 11.52% to -$5.1 million in 2010, then surged by 81.99% to -$926122.0 in 2011.
• The last three Net Income towards Common Stockholders figures came in at -$926122.0 (Q4 2011), -$5.1 million (Q4 2010), and -$5.8 million (Q4 2009), per Business Quant data.